Amneal Pharmaceuticals is a U.S.-based biopharmaceutical company that develops, manufactures, and sells prescription medicines across three segments. The core business — Affordable Medicines (~57% of revenue) — sells generic pharmaceuticals, including oral solids, injectables, biosimilars, and other complex dosage forms, to pharmacies, hospitals, and institutions. Amneal targets complex, high-barrier generics — injectables, biosimilars, inhalation products — where manufacturing difficulty and regulatory complexity limit competition and support more durable pricing. The Specialty segment (~18% of revenue) sells branded CNS and endocrine drugs, led by CREXONT and RYTARY (both carbidopa-levodopa formulations for Parkinson's disease) and UNITHROID (levothyroxine for hypothyroidism). AvKARE (~25% of revenue) distributes pharmaceuticals to the VA, DoD, and other institutional customers. Amneal sells primarily through major wholesalers — Cencora, McKesson, Cardinal Health, and CVS Health — which collectively account for about 71% of consolidated net revenue, while the Specialty segment uses a direct sales force targeting neurologists and movement disorder specialists. Amneal manufactures roughly 70% of its Affordable Medicines and Specialty products internally, with facilities in both the U.S. and India. Key growth initiatives include biosimilars (five currently marketed in the U.S., with a biosimilar to Xolair as a near-term priority), an expanded injectables portfolio targeting the hospital market, and a longer-term GLP-1 supply partnership with Metsera, a clinical-stage developer recently acquired by Pfizer.